By intervening in the hedgehog signaling pathway and the GSK‐3β signaling pathway, pirfenidone has shown an anti-fibrotic effect in interstitial lung disease secondary to systemic sclerosis. This evidence concerns the gene GSK3B and systemic sclerosis.